Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse.
LPA1 receptor
SAR100842
fibrosis
lysophosphatidic acid
systemic sclerosis
tight skin mouse
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
27
02
2019
revised:
02
03
2020
accepted:
17
06
2020
pubmed:
7
7
2020
medline:
28
5
2021
entrez:
7
7
2020
Statut:
ppublish
Résumé
Genetic deletion and pharmacological studies suggest a role for lysophosphatidic acid (LPA Dermal fibroblast and skin biopsies from systemic sclerosis patients were used. Myofibroblast differentiation, gene expression and cytokine secretion were measured following LPA and/or SAR100842 treatment. Pharmacolgical effect of SAR100842 was assessed in the tight skin 1 (Tsk1) mouse model. SAR100842 is equipotent against various LPA isoforms. Dermal fibroblasts and skin biopsies from patients with systemic sclerosis expressed high levels of LPA The effects of SAR100842 on LPA-induced inflammation and on mechanisms linked to fibrosis like myofibroblast differentiation and Wnt pathway activation indicate that LPA
Sections du résumé
BACKGROUND AND PURPOSE
Genetic deletion and pharmacological studies suggest a role for lysophosphatidic acid (LPA
EXPERIMENTAL APPROACH
Dermal fibroblast and skin biopsies from systemic sclerosis patients were used. Myofibroblast differentiation, gene expression and cytokine secretion were measured following LPA and/or SAR100842 treatment. Pharmacolgical effect of SAR100842 was assessed in the tight skin 1 (Tsk1) mouse model.
KEY RESULTS
SAR100842 is equipotent against various LPA isoforms. Dermal fibroblasts and skin biopsies from patients with systemic sclerosis expressed high levels of LPA
CONCLUSION AND IMPLICATIONS
The effects of SAR100842 on LPA-induced inflammation and on mechanisms linked to fibrosis like myofibroblast differentiation and Wnt pathway activation indicate that LPA
Identifiants
pubmed: 32627178
doi: 10.1111/bph.15190
pmc: PMC7443477
doi:
Substances chimiques
Receptors, Lysophosphatidic Acid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4296-4309Subventions
Organisme : Target Bio Science
Organisme : Roche
Organisme : Pfizer
Organisme : Merck Sharp and Dohme
Organisme : Mitsubishi Tanabe Pharma Corporation
Organisme : Medscape
Organisme : medac
Organisme : Eli Lilly and Company
Organisme : Kymera Therapeutics
Organisme : iQvia
Organisme : iQone
Organisme : Italfarmaco
Organisme : Horizon (Curzion) Pharmaceuticals
Organisme : Glenmark Pharmaceuticals
Organisme : Ergonex
Organisme : ChemomAb
Organisme : CSL Behring
Organisme : Drug Development International Ltd
Organisme : Competitive Corpus
Organisme : Catenion
Organisme : Blade Therapeutics
Organisme : Baecon Discovery
Organisme : Amgen
Organisme : Acceleron
Organisme : Actelion Pharmaceuticals
Organisme : AbbVie
Organisme : UCB
Organisme : RedX
Organisme : Novartis
Organisme : Inventiva
Organisme : GlaxoSmithKline
Organisme : Galapagos NV
Organisme : Celgene
Organisme : Boehringer Ingelheim
Organisme : Bayer
Organisme : Bristol-Myers Squibb
Organisme : aTyr
Organisme : ARXX
Organisme : Array BioPharma
Organisme : Active Biotech
Organisme : Anamar
Organisme : Sanofi
Informations de copyright
© 2020 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Arthritis Rheum. 2011 May;63(5):1405-15
pubmed: 21305523
Biochem Biophys Res Commun. 2011 May 27;409(1):7-13
pubmed: 21545790
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
Expert Opin Investig Drugs. 2011 May;20(5):657-67
pubmed: 21434838
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
Int J Mol Sci. 2009 Jul 13;10(7):3194-208
pubmed: 19742132
Arthritis Rheumatol. 2018 Oct;70(10):1634-1643
pubmed: 29732731
Int J Med Sci. 2009 Jun 05;6(4):168-76
pubmed: 19521548
Nat Commun. 2012 Mar 13;3:735
pubmed: 22415826
J Invest Dermatol. 2008 Apr;128(4):871-81
pubmed: 17943183
Br J Pharmacol. 2010 Aug;160(7):1699-713
pubmed: 20649573
Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii3-7
pubmed: 19487220
J Invest Dermatol. 2005 Sep;125(3):421-7
pubmed: 16117781
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Naunyn Schmiedebergs Arch Pharmacol. 1997 Jan;355(1):1-7
pubmed: 9007835
Prog Lipid Res. 2003 Nov;42(6):498-526
pubmed: 14559069
Clin Exp Immunol. 1998 Nov;114(2):293-300
pubmed: 9822290
J Lipid Res. 2014 Jul;55(7):1192-214
pubmed: 24643338
Arthritis Rheum. 2012 Aug;64(8):2734-45
pubmed: 22328118
Curr Opin Rheumatol. 2013 Nov;25(6):679-85
pubmed: 24047603
Cell Signal. 2006 Oct;18(10):1695-701
pubmed: 16504475
Prog Lipid Res. 2007 Mar;46(2):145-60
pubmed: 17459484
J Immunol. 2004 Apr 1;172(7):4480-5
pubmed: 15034064
Ann Rheum Dis. 2014 Oct;73(10):1880-7
pubmed: 23918036
J Biol Chem. 2009 Jun 19;284(25):17304-19
pubmed: 19366702
Br J Pharmacol. 2014 Aug;171(15):3575-94
pubmed: 24602016
Br J Pharmacol. 2018 Feb;175(3):407-411
pubmed: 29350411
Arthritis Rheumatol. 2016 Dec;68(12):2964-2974
pubmed: 27390295
Nat Med. 2015 Feb;21(2):150-8
pubmed: 25581517
Ann Rheum Dis. 2013 Dec;72(12):2039-46
pubmed: 24013728
Br J Pharmacol. 2019 Dec;176 Suppl 1:S21-S141
pubmed: 31710717
Br J Pharmacol. 2020 Sep;177(18):4296-4309
pubmed: 32627178
Nat Med. 2008 Jan;14(1):45-54
pubmed: 18066075
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Am Rev Respir Dis. 1988 Mar;137(3):579-84
pubmed: 3345039